[Secondary osteoporosis or secondary contributors to bone loss in fracture. Abnormal bone metabolism in pulmonary diseases].
Abnormal bone metabolism in pulmonary diseases has been recently investigated mainly in COPD, as well as osteoporosis induced by glucocorticoid therapy for lung diseases. COPD involves not only the lungs but also extrapulmonary abnormalities as systemic effects. Of these comorbidities, osteoporosis has been becoming an important target for therapeutic intervention in the management of COPD. This paper reviews the abnormal bone metabolism associated with pulmonary diseases including COPD.